| Predictive value of proliferating cell nuclear antigen index in response to interferon treatment in patients with chronic viral hepatitis B and C | Zeki KARASU,FUNDA YILMAZ BARBET,Galip ERSÖZ,Fulya GÜNŞAR,Yücel BATUR,Ulus S. AKARCA | 89–94 |
| Comparison of terlipressin plus sclerotherapy with somatostatin plus sclerotherapy to control bleeding from esophageal varices in with child C cirrhosis patients | Ali HAFTA,Aziz YAZAR,Cengiz PATA | 95–99 |
| Active factor VII levels in patients with cirrhosis | Fahri IŞITAN,Levent ÜNDAR,Cemal ERTUĞRUL,İnci SÜLEYMANLAR | 100–103 |
| Biliary tract abnormalities in patients with autosomal dominant polycystic kidney disease: Incidence and magnetic resonance cholangiopancreatography findings | Murat GÜRSOY,Beril AKMAN,Muhteşem AĞILDERE,Aslı DOĞRUK,Cüneyt AYTEKİN,Nurhan ÖZDEMİR,Sedat BOYACIOĞLU | 104–109 |
| Complications in rats created by human bile and gallstones | Barış ZAMANDAR,Erhan AKGÜN,Adem GÜLER,Özer İLKGÜL,Gökhan İÇÖZ,Ömer ÖZÜTEMİZ | 110–112 |
| Does omeprazole alter the salivary gland functions? | Vildan TAŞKIN,Hülya ORTAPAMUK,Esin ÖZYILKAN,Faruk ÇETİN,Erdal ESKİOĞLU,Tankut KÖSEOĞLU,Seniha NALDÖKEN | 113–116 |
| Comparison of lansoprazole and omeprazole treatment in grade II and III reflux esophagitis | Sadık YILDIRIM,Levent ERDEM,Hakan M. KÖKSAL,Adil BAYKAN | 117–121 |
| Acid reduction and Helicobacter pylori treatment in pyloric stenosis: A prospective study | Sadık YILDIRIM,Levent ERDEM,Hakan M. KÖKSAL,Adil BAYKAN,Halil İ. MEDE,Ömer KURT | 122–125 |
| Can resistant Helicobacter pylori infection be estimated histologically: Effects of gastric histology on eradication rates of Helicobacter pylori infection | Vildan TAŞKIN,Esin ÖZYILKAN,Abdullah AYDIN,Faruk ÇETİN,Erdal ESKİOĞLU,Tankut KÖSEOĞLU | 126–129 |
| Immunohistochemical analysis of primary gastric lymphomas | Gülen DOĞUSOY,Anık Ferah KARAYEL,Selda GÖÇENER,Süha GÖKSEL | 130–135 |
| Serum eosinophilic cationic protein: A marker of eosinophilic infiltration in inflammatory bowel disease? |